NGS Based RNA Sequencing Market is growing at a CAGR of 19.7%, Precision Medicine dominate 40% market share| Key Players:- Illumina, Inc., Oxford Nanopore Technologies, Agilent Technologies.

NGS based RNA Sequencing Market is predicted to reach at a CAGR of 19.7% during the forecast period (2024-2031). NGS-Based RNA-Sequencing is a technology used in identifying and determining the order of nucleotides in an RNA sequence.

The NGS-based RNA sequencing market is growing due to increasing demand for precision medicine, rising genomics research, advancements in sequencing technologies, growing applications in biomarker discovery, drug development, and disease diagnostics, alongside decreasing costs and faster, high-throughput RNA analysis.

Download your exclusive free sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/ngs-based-rna-sequencing-market?pratik

United States: Key Industry Developments:-
✅ November 2025: BGI Americas partnered with major U.S. hospitals and biotech firms to deploy cloud-based NGS RNA sequencing pipelines, enhancing AI-driven diagnostics and precision medicine workflows for immunotherapy research.​

✅ October 2025: PacBio launched a next-generation long-read RNA sequencing system tailored for full-length transcript analysis, enabling U.S. researchers to better detect alternative splicing and gene isoforms in biomarker discovery.​

✅ September 2025: Roche introduced sequencing by expansion (SBX) technology for NGS-based RNA sequencing, offering ultra-rapid, high-throughput analysis scalable for complex disease studies like cancer and neurodegeneration.​

Japan: Key Industry Developments:-
✅ November 2025: Takara Bio released advanced NGS RNA sequencing kits optimized for single-cell and spatial transcriptomics, supporting Japan's oncology and regenerative medicine research initiatives.​

✅ October 2025: RIKEN collaborated with local biotech firms to install high-throughput NGS RNA sequencing platforms in research hospitals, advancing national precision medicine programs for genetic disease studies.​

✅ February 2025: MGI Tech unveiled DNBSEQ-T1+ and DNBSEQ-E25 Flash sequencers, providing high-performance RNA sequencing solutions to boost genomics research efficiency in Japan.

→ 2025 M&A Data:-
September 2, 2025: SeqOne completed the acquisition of Congenica, integrating its AI‐driven genomic analysis platform with Congenica's clinical interpretation technology to create a global leader in NGS data interpretation and transcriptomics‐related workflows, significantly expanding its footprint across 160+ labs worldwide.

April 2025: SeqOne Genomics acquired Life & Soft, enhancing its multi‐omics and transcriptomics analysis capabilities by integrating Life & Soft's ISO‐certified sequencing and analysis platform into its broader NGS offerings, strengthening solutions for RNA‐seq data workflows and clinical diagnostics applications.

April 2025: QIAGEN made a strategic acquisition of Genoox, an NGS data analysis software provider, adding advanced bioinformatics capabilities that support genomic interpretation across NGS workflows, including RNA sequencing, improving clinical and research analytics scalability.

"Secure your 30% year-end discount - get this report before the offer expires.":https://www.datamintelligence.com/buy-now-page?report=ngs-based-rna-sequencing-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

→ Market Segmenatation-

By Product & Services
Sequencing platforms & consumables: 58% share, USD 2.46B - driven by high demand for reagents and high-throughput instruments.
Sequencing services: 17% share, USD 0.72B - fueled by outsourcing in research and clinical workflows.

By Technology
Sequencing by Synthesis (SBS): 50% share, USD 2.12B - high accuracy and cost-effective.
Nanopore Sequencing: 22% share, USD 0.93B - real-time, long-read sequencing.
Ion Semiconductor Sequencing: 14% share, USD 0.59B - portable and fast.
Single-Molecule Real-Time (SMRT) Sequencing: 14% share, USD 0.59B - suitable for diverse applications.

By Application
Precision Medicine: 40% share, USD 1.69B - personalized therapies and biomarker identification.
Drug Discovery: 27% share, USD 1.14B - target validation and screening.
Others (research profiling, academic studies): 33% share, USD 1.40B - supporting broader genomics research.

→ Key Regional Insights
• North America - 44% share: North America remains the largest regional market for NGS‐based RNA sequencing, driven by strong genomics R&D infrastructure, significant government and private research funding, and adoption across academic, clinical, and biotech sectors.

• Europe - 28% share: Europe holds a significant share of the market, backed by robust public genomics programs, collaboration among research institutions, and broad adoption of RNA‐seq for clinical and pharmaceutical research initiatives.

• Asia‐Pacific - 25% share: Asia‐Pacific contributes a substantial portion of the market, with rapid growth fueled by increasing investments in genomic research programs and rising adoption in China, Japan, and India.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/ngs-based-rna-sequencing-market?pratik

→ Market Players:-
The global NGS based RNA Sequencing Market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc., F. Hoffmann-La Roche Ltd, Hamilton Company, and Takara Bio Inc. among others.

Illumina, Inc.
Illumina dominates with its sequencing by synthesis (SBS) technology, offering high-throughput, accurate RNA sequencing platforms widely used in transcriptomics and precision medicine. The company holds the largest market share at approximately 65% in NGS overall, extending strongly to RNA applications through integrated workflows and consumables.​

Thermo Fisher Scientific Inc.
Thermo Fisher excels in comprehensive solutions including Ion Torrent systems for targeted RNA sequencing, supported by robust sample prep and bioinformatics tools. It captures around 17% market share, driven by its end-to-end ecosystem popular in clinical and pharma settings.​

Oxford Nanopore Technologies
Oxford Nanopore leads in nanopore-based long-read sequencing, enabling real-time RNA analysis for complex transcript isoforms and epitranscriptomics. Its market share stands at about 6%, growing rapidly due to portability and cost-effectiveness in emerging markets.

→ Primary Market Growth Drivers
1. Expansion of Precision & Personalized Medicine
RNA sequencing is central to precision medicine because it provides detailed gene expression profiles that help tailor treatments to individual patients-especially in oncology, rare diseases, and complex disorders. Growing emphasis on precision healthcare and the integration of RNA‐Seq into clinical decision‐making significantly boosts market demand.

2. Technological Advancements & Platform Innovations
Continuous improvements in NGS platforms (higher throughput, enhanced accuracy, reduced cost per run) are key drivers. Advances such as single‐cell RNA‐Seq, long‐read technologies, automated workflows, and integration with AI/bioinformatics tools make RNA sequencing more efficient and accessible.

3. Increasing R&D Investment
Rising research activities in genomics, drug discovery, biomarker identification, and transcriptomics fuel adoption. Higher funding from government bodies, academic institutions, and pharmaceutical companies supports larger sequencing projects and drives market expansion.

4. Expanding Clinical Applications
Beyond basic research, RNA‐Seq is increasingly used in clinical diagnostics-particularly for cancer profiling, biomarker discovery, prognosis, and treatment response monitoring. These clinical roles enhance the commercial value of RNA sequencing tools.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.